Use the search bar to search by drug, manufacturer, or indication. You can also filter your search results by drug, manufacturer, or negotiation status.
To learn more about a specific file, click on a drug name. It will open its product card, which includes information about the manufacturer, indication (the approved use of a drug by Health Canada), and negotiation milestones.
There are 6 negotiation statuses, which reflect where the drug file is in the pCPA process:
Under consideration for negotiation
We’re considering the evidence and gathering other information to inform the negotiation approach, including eligibility for expedited negotiation pathways.
Active negotiation
Negotiation activities are underway for the drug, with our negotiation team and the manufacturer meeting regularly.
Concluded with an LOI
Negotiations ended successfully with mutually agreed-upon terms, and these terms are outlined in a letter of intent (LOI).
Concluded without agreement
Negotiating parties couldn’t agree on terms. Negotiations have ended without a pricing agreement for the drug.
Negotiation not pursued
It has been decided, in partnership with our member drug plans, not to engage in a negotiation. Typically, this is because the drug’s health technology (HTA) assessment reimbursement recommendations were negative, or “do not reimburse.” Other reasons, like the manufacturer declining to negotiate or a lack of supply of the drug in Canada, may be reflected in an accompanying status note.
Negotiation on hold
We began negotiation activities for the drug, but they’ve since been paused. An accompanying status note indicates whether the pause was requested by the manufacturer or the pCPA.
Learn more
To learn more about our negotiation processes, or where the pCPA fits into the Canadian drug reimbursement system, consult these pages:
Status:
Concluded with an LOI
Manufacturer:
Biogen Canada Inc.
Indication:
Neovascular (wet) age-related macular degeneration (AMD), or visual impairment due to diabetic macular edema (DME), macular edema secondary to retinal vein occlusion (RVO), choroidal neovascularisation (CNV) secondary to pathologic myopia (PM), choroidal neovascularisation (CNV) secondary to ocular conditions other than AMD or PM, including but not limited to angioid streaks, post-inflammatory retinochoroidopathy, central serous chorioretinopathy or idiopathic chorioretinopathy
Last updated:
May 11, 2023
Status:
Concluded with an LOI
Manufacturer:
Eisai Limited
Indication:
Advanced endometrial carcinoma that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR), in adult patients who have disease progression following prior platinum-based systemic therapy, and are not candidates for curative surgery or radiation (in combination with pembrolizumab)
Last updated:
May 10, 2023
Status:
Concluded with an LOI
Manufacturer:
Eisai Limited
Indication:
Advanced or metastatic renal cell carcinoma (RCC) with no prior systemic therapy for metastatic renal cell carcinoma (RCC), in adult patients (In combination with pembrolizumab)
Last updated:
May 10, 2023
Status:
Concluded with an LOI
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Acute Graft-Versus-Host disease
Last updated:
May 5, 2023
Status:
Concluded with an LOI
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Chronic Graft-versus-host Disease
Last updated:
May 5, 2023
Wakix (pitolisant hydrochloride)
Status:
Concluded without agreement
Manufacturer:
Paladin Labs Inc.
Indication:
Excessive daytime sleepiness or cataplexy in adult patients with narcolepsy
Last updated:
May 3, 2023
Status:
Concluded with an LOI
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Diabetic Macular Edema
Last updated:
April 27, 2023
Status:
Concluded with an LOI
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Neovascular (Wet) Age-related Macular Degeneration (nAMD)
Last updated:
April 27, 2023
Status:
Concluded with an LOI
Manufacturer:
Alnylam Netherlands B.V.
Indication:
Acute Hepatic Porphyria
Last updated:
April 27, 2023
Firdapse (amifampridine phosphate)
Status:
Concluded with an LOI
Manufacturer:
KYE Pharmaceuticals Inc.
Indication:
Lambert-Eaton Myasthenic Syndrome (LEMS)
Last updated:
April 25, 2023